| Literature DB >> 28558660 |
Yu Jun Li1,2, Chu Zhi Pan3, Chang Quan Fang4, Zhu Xiang Zhao2, Hui Ling Chen5, Peng Hao Guo6, Zi Wen Zhao7.
Abstract
BACKGROUND: The clonal spread of multiple drug-resistant Acinetobacter baumannii is an emerging problem in China. We analysed the molecular epidemiology of Acinetobacter baumanni isolates at three teaching hospitals and investigated the risk factors, clinical features, and outcomes of hospital-acquired pneumonia caused by extensive drug-resistant Acinetobacter baumannii (XDRAB) infection in Guangzhou, China.Entities:
Keywords: Acinetobacter baumannii; Extensive drug resistance; Multilocus sequence typing; Pneumonia; bla OXA-51-like gene
Mesh:
Substances:
Year: 2017 PMID: 28558660 PMCID: PMC5450129 DOI: 10.1186/s12879-017-2471-0
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Characteristics of the 52 A. baumannii isolates
| Number of isolates | Hospital | Specimens | Wards | gltA | gyrB | gdhB | recA | cpn60 | gpi | rpoD | ST | CC |
| Phenotype | XDRAB pneumonia |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | GFPH | Sputum | ICU | 1 | 3 | 3 | 2 | 2 | 97 | 3 | ST208 | 92 | OXA-66 | XDR | Yes |
| 2 | GFPH | Blood | ICU | 1 | 3 | 3 | 2 | 2 | 96 | 5 | STn1 | 92 | OXA-66 | XDR | Yes |
| 3 | GFPH | Sputum | ICU | 1 | 3 | 3 | 2 | 2 | 97 | 3 | ST208 | 92 | OXA-66 | XDR | Yes |
| 4 | GFPH | Blood | ICU | 1 | 3 | 3 | 2 | 2 | 96 | 3 | ST195 | 92 | OXA-66 | XDR | Yes |
| 5 | GFPH | BALF | RICU | 1 | 3 | 3 | 2 | 2 | 96 | 3 | ST195 | 92 | OXA-66 | XDR | Yes |
| 6 | GFPH | Sputum | RICU | 1 | 3 | 3 | 2 | 2 | 96 | 3 | ST195 | 92 | OXA-66 | MDR | No |
| 7 | GFPH | Sputum | Respiratory | 1 | 15 | 3 | 2 | 2 | 153 | 3 | ST457 | 92 | OXA-66 | XDR | No |
| 8 | GFPH | Sputum | RICU | 1 | 3 | 3 | 2 | 2 | 96 | 3 | ST195 | 92 | OXA-66 | XDR | Yes |
| 9 | GFPH | Sputum | ICU | 1 | 3 | 3 | 2 | 2 | 96 | 3 | ST195 | 92 | OXA-66 | XDR | Yes |
| 10 | GFPH | Sputum | Respiratory | 1 | 3 | 3 | 2 | 2 | 97 | 3 | ST208 | 92 | OXA-66 | XDR | yes |
| 11 | GFPH | Sputum | Neurosurgery | 1 | 15 | 3 | 2 | 2 | 96 | 3 | STn2 | 92 | OXA-199 | XDR | Yes |
| 12 | GFPH | Sputum | RICU | 1 | 3 | 3 | 2 | 2 | 96 | 3 | ST195 | 92 | OXA-66 | MDR | No |
| 13 | GFPH | Sputum | Respiratory | 1 | 3 | 3 | 2 | 2 | 97 | 3 | ST208 | 92 | OXA-66 | XDR | No |
| 14 | GFPH | Sputum | ICU | 1 | 3 | 3 | 2 | 2 | 96 | 3 | ST195 | 92 | OXA-66 | MDR | No |
| 15 | GFPH | BALF | RICU | 1 | 3 | 3 | 2 | 2 | 96 | 3 | ST195 | 92 | OXA-66 | XDR | yes |
| 16 | GFPH | Sputum | ICU | 1 | 3 | 3 | 2 | 2 | 96 | 3 | ST195 | 92 | OXA-66 | XDR | yes |
| 17 | GFPH | Wound | Gastroenterology | 1 | 3 | 3 | 2 | 2 | 96 | 3 | ST195 | 92 | OXA-66 | XDR | No |
| 18 | GFPH | Sputum | Respiratory | 1 | 3 | 3 | 2 | 2 | 97 | 3 | ST208 | 92 | OXA-66 | XDR | No |
| 19 | GFPH | Sputum | ICU | 1 | 3 | 3 | 2 | 2 | 97 | 3 | ST208 | 92 | OXA-66 | XDR | yes |
| 20 | GFPH | Urine | Geriatrics ICU | 21 | 15 | 3 | 2 | 35 | 111 | 4 | ST254 | singletons | OXA-66 | XDR | No |
| 21 | GFPH | BALF | RICU | 1 | 3 | 3 | 2 | 2 | 96 | 3 | ST195 | 92 | OXA-66 | XDR | yes |
| 22 | GFPH | BALF | RICU | 1 | 3 | 3 | 2 | 2 | 96 | 3 | ST195 | 92 | OXA-66 | MDR | No |
| 23 | GFPH | Sputum | Respiratory | 1 | 3 | 3 | 2 | 2 | 97 | 3 | ST208 | 92 | OXA-66 | XDR | yes |
| 24 | GFPH | Sputum | ICU | 1 | 3 | 3 | 2 | 2 | 97 | 3 | ST208 | 92 | OXA-66 | MDR | No |
| 25 | GFPH | Sputum | RICU | 1 | 3 | 3 | 2 | 2 | 96 | 3 | ST195 | 92 | OXA-66 | XDR | yes |
| 26 | GFPH | Sputum | RICU | 1 | 3 | 3 | 2 | 2 | 96 | 3 | ST195 | 92 | OXA-66 | XDR | yes |
| 27 | GFPH | Sputum | Neurosurgery | 1 | 81 | 3 | 2 | 2 | 96 | 4 | STn3 | singletons | OXA-66 | MDR | No |
| 28 | GFPH | Sputum | Respiratory | 21 | 15 | 3 | 2 | 35 | 111 | 4 | ST254 | singletons | OXA-66 | XDR | yes |
| 29 | GFPH | Sputum | RICU | 21 | 15 | 3 | 2 | 35 | 111 | 4 | ST254 | singletons | OXA-66 | XDR | yes |
| 30 | GFPH | Sputum | RICU | 1 | 3 | 3 | 2 | 2 | 96 | 3 | ST195 | 92 | OXA-66 | XDR | No |
| 31 | GFPH | Sputum | Respiratory | 1 | 3 | 3 | 2 | 2 | 97 | 3 | ST208 | 92 | OXA-66 | XDR | yes |
| 32 | GFPH | Sputum | Neurosurgery | 1 | 81 | 3 | 2 | 2 | 96 | 4 | STn3 | singletons | OXA-66 | MDR | No |
| 33 | GFPH | Sputum | ICU | 1 | 3 | 3 | 2 | 2 | 96 | 3 | ST195 | 92 | OXA-66 | XDR | Yes |
| 34 | GFPH | BALF | RICU | 1 | 15 | 3 | 2 | 2 | 153 | 3 | ST457 | 92 | OXA-66 | XDR | Yes |
| 35 | GFPH | CSF | ICU | 1 | 3 | 3 | 2 | 2 | 96 | 3 | ST195 | 92 | OXA-66 | XDR | No |
| 36 | GFPH | Sputum | Respiratory | 21 | 15 | 3 | 2 | 35 | G1 | 3 | STn4 | singletons | OXA-66 | MDR | No |
| 37 | GFPH | Sputum | ICU | 1 | 3 | 3 | 2 | 2 | 96 | 3 | ST195 | 92 | OXA-66 | XDR | No |
| 38 | GFPH | Wound | Burn | A1 | 15 | 3 | 2 | 2 | 153 | 4 | STn5 | 92 | OXA-66 | XDR | No |
| 39 | GFPH | Sputum | Geriatrics ICU | 21 | 15 | 3 | 2 | 35 | G1 | 3 | STn4 | singletons | OXA-66 | XDR | No |
| 40 | GFPH | Blood | Urinary surgery | 1 | 3 | 3 | 2 | 2 | 96 | 3 | ST195 | 92 | OXA-66 | XDR | No |
| 41 | GFPH | Sputum | Nephrology | 1 | 3 | 3 | 2 | 2 | 97 | 3 | ST208 | 92 | OXA-66 | MDR | No |
| 42 | GFPH | BALF | RICU | 11 | 65 | 3 | 20 | 37 | 96 | 15 | STn6 | singletons | OXA-66 | MDR | No |
| 43 | FAH | Sputum | ICU | 1 | 3 | 3 | 2 | 2 | 96 | 3 | ST195 | 92 | OXA-66 | MDR | N/A |
| 44 | FAH | Sputum | ICU | 1 | 3 | 3 | 2 | 2 | 96 | 3 | ST195 | 92 | OXA-66 | XDR | N/A |
| 45 | FAH | Sputum | ICU | 33 | 31 | 2 | 28 | 1 | 96 | 5 | STn7 | singletons | OXA-66 | MDR | N/A |
| 46 | FAH | Sputum | ICU | 1 | 3 | 3 | 2 | 2 | 97 | 3 | ST208 | 92 | OXA-66 | MDR | N/A |
| 47 | TAH | Sputum | ICU | 1 | 3 | 3 | 2 | 2 | 96 | 3 | ST195 | 92 | OXA-66 | MDR | N/A |
| 48 | TAH | Sputum | ICU | 1 | 3 | 3 | 2 | 2 | 16 | 3 | ST136 | 92 | OXA-66 | XDR | N/A |
| 49 | TAH | Sputum | ICU | 1 | 3 | 3 | 2 | 2 | 96 | 3 | ST195 | 92 | OXA-66 | MDR | N/A |
| 50 | TAH | Sputum | ICU | 1 | 3 | 3 | 2 | 2 | 97 | 3 | ST208 | 92 | OXA-66 | MDR | N/A |
| 51 | TAH | Sputum | ICU | 1 | 3 | 3 | 2 | 2 | 96 | 3 | ST195 | 92 | OXA-66 | MDR | N/A |
| 52 | TAH | Sputum | ICU | 1 | 3 | 3 | 2 | 2 | 16 | 3 | ST136 | 92 | OXA-66 | XDR | N/A |
GFPH Guangzhou First People’s Hospital, FAH the First Affiliated Hospital of Sun Yat-sen University, TAH the Third Affiliated Hospital of Sun Yat-sen University, BALF bronchoalveolar lavage fluid, CSF cerebrospinal fluid, ICU intensive care unit, RICU respiratory intensive care unit, G1 a new allele that has a T → C mutation at nt3 in the gpi111 locus; A1 a new allele possessing two mutations at the gltA1 locus (A → C mutations at nt156 and nt159); N/A not available
The relationship between the clonal complex (CC) and resistance phenotype of the 52 A. baumannii isolates
| Clonal complex | No. isolates | MDR | XDR | Statistical analysisa | |
|---|---|---|---|---|---|
| χ2 -values |
| ||||
| CC92 | 43 | 14 (32.6) | 29 (67.4) | 0.088 | 0.767 |
| ST195 | 24 | 9 | 15 | ||
| ST208 | 12 | 5 | 7 | ||
| ST457 | 2 | 0 | 2 | ||
| ST136 | 2 | 0 | 2 | ||
| STn1 | 1 | 0 | 1 | ||
| STn2 | 1 | 0 | 1 | ||
| STn5 | 1 | 0 | 1 | ||
| Non-CC92 | 9 | 4 (44.4) | 5 (55.6) | ||
| ST254 | 3 | 0 | 3 | ||
| STn3 | 2 | 2 | 0 | ||
| STn4 | 2 | 0 | 2 | ||
| STn6 | 1 | 1 | 0 | ||
| STn7 | 1 | 1 | 0 | ||
a comparison of CC92 with non-CC92 strains
Fig. 1Population snapshot of A. baumannii in this study and other existing isolates in China. Population snapshot of A. baumannii in this study and existing isolates in China based on the data contained in the Pubmlst database as of 27 April 2013 [5, 18] represented by an eBURST algorithm. Circles represent STs, and their sizes correspond to the numbers of isolates. The red circle represents the founder ST (ST92). The broken line indicates clonal complex (CC) 92. The ST labels are coloured as follows: black, STs found only in the Pubmlst database; green, STs found only in this study; and purple, STs found in both the Pubmlst database and this study. ST254, STn3, STn4, STn6 and STn7 were the singletons in this study
Comparison of clinical data for pneumonia-related characteristics in HAP patients with XDRAB and non-XDRAB
| XDRAB | Non-XDRAB |
| |
|---|---|---|---|
| Age, ya | 77.5 ± 11.6 | 68.6 ± 18.4 | 0.023 |
| Gender (M/F), n | 17/4 | 23/19 | 0.079 |
| APACHE II scorea | 21.9 ± 6.8 | 18.0 ± 4.9 | 0.011 |
| Related to hospitalizationa | 18 (85.7) | 30 (71.4) | 0.347 |
| Days of mechanical ventilation before XDRAB (days) | 10.5 ± 11.6 | 5.2 ± 5.8 | 0.059 |
| Hospital days before XDRAB (days) | 18.3 ± 11.3 | 12.6 ± 11.2 | 0.064 |
| Length of stay in the ICU (days) | 30.1 ± 20.0 | 21.4 ± 21.7 | 0.127 |
| Length of stay in the hospital (days) | 45.5 ± 28.8 | 38.5 ± 24.2 | 0.199 |
| Associated disease, n (%) | |||
| COPD | 13 (61.9) | 9 (21.4) | 0.001 |
| Diabetes mellitus | 2 (9.5) | 10 (40.4) | 0.307 |
| Malignancy | 2 (9.5) | 9 (21.4) | 0.411 |
| Cardiac disease | 13 (61.9) | 6 (14.2) | 0.000 |
| Renal disease | 5 (23.8) | 2 (4.7) | 0.065 |
| Neurological disease | 8 (38.0) | 22 (52.3) | 0.422 |
| Device, n (%) | |||
| Urinary catheter | 21 (100.0) | 36 (85.7) | 0.172 |
| Nasogastric tube | 21 (100.0) | 36 (85.7) | 0.172 |
| Mechanical ventilation | 16 (76.1) | 31 (73.8) | 1.000 |
| Drug usage, n (%) | |||
| Glucocorticoids | 10 (47.6) | 18 (42.8) | 0.720 |
| PPIs | 14 (66.7) | 32 (76.1) | 0.422 |
| Antimicrobial n (%) | |||
| Cephalosporin | |||
| Second generation | 3 (14.2) | 5 (11.9) | 1.000 |
| Third generation | 7 (33.3) | 18 (42.8) | 0.649 |
| β-lactamase inhibitor | 20 (95.2) | 31 (73.8) | 0.089 |
| Quinolone | 13 (61.9) | 19 (45.2) | 0.327 |
| Aminoglycoside | 2 (9.5) | 4 (9.5) | 1.000 |
| Carbapenem | 11 (52.3) | 11 (26.1) | 0.040 |
| Antimicrobial Combination therapy, n (%) | 11 (52.3) | 19 (45.2) | 0.593 |
| Mortality, n (%) | 9 (42.8) | 15 (35.7) | 0.582 |
aValues are presented as the mean ± standard deviation; malignancy includes haematological malignancies and solid tumours; cardiac disease includes coronary artery disease, hypertensive heart disease, valvular disease and cardiomyopathy; renal disease includes chronic renal failure; neurological disease includes cerebral haemorrhage and cerebral infarction; PPIs proton pump inhibitor drugs
Multi-variate analysis of risk factors for patients with XDRAB pneumonia
| Risk factor | OR (95% CI) |
|
|---|---|---|
| APACHE II score | 1.17 (1.01–1.35) | 0.034 |
| COPD | 7.25 (1.54–33.9) | 0.012 |
| Cardiac disease | 6.94 (1.43–33.6) | 0.016 |